Latest Biotechnology, Pharmaceutical and Healthcare News

02:36 EDT 3rd August 2015 | BioPortfolio

Showing News Articles 1–25 of 410,000+

Monday 3rd August 2015

BRIEF-Clinigen says Martin Abell to join as CFO-elect immediately

* Martin Abell will join group as an executive director and CFO Elect with immediate effect. Source text for Eikon: Further company coverage:

BRIEF-Dechra Pharma to acquire 63.3 pct shareholding in Genera dd

* Dechra to acquire 63.3 pct shareholding in Genera D.D. (19.4 mln stg)

BRIEF-AstraZeneca, Isis Pharmaceuticals announce strategic collaboration

* AstraZeneca and Isis Pharmaceuticals to discover and develop antisense drugs for cardiovascular, metabolic and renal diseases

Swiss stocks - Factors to watch on Aug 3

ZURICH, Aug 3 (Reuters) - The Swiss blue-chip SMI was seen opening 0.2 percent lower at 9,411 points on Monday, according to premarket indications by bank Julius Baer .

Your Hearing Network Partners with Tinnitus Treatment Solutions to Provide Expert Care to Those Suffering with Ringing in the Ears

First corporate partnership to provide nationwide expert tinnitus care and next-generation sound therapy technology. Your Hearing Network (YHN), a network of over 1,800 audiology and hearing care professional service provider locations, and

US Capitol Capsule: The vaccine pursuit: Not for the faint of heart

With the successes in the past few weeks of vaccines for Ebola and malaria – both being described as game-changers for the diseases they are intended to prevent – the industry and researchers have much to celebrate.

BRIEF-China's Da An Gene plans to set up industry fund worth 303 mln yuan with partners

Aug 3 (Reuters) - Da An Gene Co Ltd of Sun Yat-Sen University

BRIEF-Celyad completes final patient infusion in CHART-1 phase III trial

* Announced that it has completed the injection procedure for the last patient enrolled in CHART-1, its European Phase III clinical trial for its lead cardiovascular disease product candidate, C-Cure Source text for Eikon: Further company coverage: (...

BRIEF-Ipsen says its partner, Lexicon Pharmaceuticals, announces positive results from Telestar Phase 3 study

* Ipsen's partner, Lexicon Pharmaceuticals, announces positive results from Telestar Phase 3 study showing that telotristat etiprate is effective in the treatment of carcinoid syndrome caused by neuroendocrine tumors not ade

Ipsen’s Partner, Lexicon Pharmaceuticals, Announces Positive Results from TELESTAR Phase 3 Study Showing That Telotristat Etiprate is Effective in the Treatment of Carcinoid Syndrome Caused by Neuroendocrine Tumors Not Adequately Controlled by Somatosta

Regulatory News: Ipsen’s Partner, Lexicon Pharmaceuticals, Announces Positive Results from TELESTAR Phase 3 Study Showing That Telotristat Etiprate is Effective in the Treatment of Carcinoid Syndrome Caused by Neuroendocrine Tumors Not Adequately Controlled by Somatostatin Analogs Telotristat etiprate met the primary endpoint, ...

Could you be the next Student Nursing Times editor? Applications now open!

Each year, we recruit four student nurses to be the faces of Student NT and to represent their branch of nursing. Applications are now open for student editors for 2015/16

BRIEF-Zhejiang Nhu's H1 net profit down 66.2 pct y/y

* Says H1 net profit down 66.2 percent y/y at 185.6 million yuan ($29.89 million)

New cocktails to test limits of cancer drug pricing

LONDON (Reuters) - New cancer drug cocktails set to reach the market in the next few years will test the limits of premium pricing for life-saving medicines, forcing company executives to consider fresh market strategies.

Sunday 2nd August 2015

Dechra to Acquire 63.3% Shareholding (£19.4m) in Genera d.d. Croatia

LONDON, August 3, 2015 /PRNewswire/ -- Mandatory takeover offer for the remaining shares  Dechra Pharmaceuticals PLC ("Dechra" or the "Company") is pleased to announce the signing of a conditional share purchase agreement ("SPA") with Mr. Marijan Hanžeković to acquire his 63.3% holding (equivalent to 69% voting rights) in Genera d.d. ("Genera"), a Croatian listed pharmaceutical b...

AstraZeneca and Isis Pharmaceuticals to Discover and Develop Antisense Drugs for Cardiovascular, Metabolic and Renal Diseases

CARLSBAD, Calif., Aug. 3, 2015 /PRNewswire/ -- Isis Pharmaceuticals, Inc. (NASDAQ: ISIS) and AstraZeneca today announced a strategic collaboration to discover and develop antisense therapies for cardiovascular, metabolic and renal diseases. The new collaboration builds on a broad existing relationship between the two companies and supports AstraZeneca's strategic approach in these therapeutic...

China Pushes For Lower Sovaldi Prices Amid Rising HCV Cases

Excluded from an access program targeting low-income countries, China is now working to secure lower prices for hepatitis C drug Sovaldi via negotiations with manufacturer Gilead Sciences, hoping to bring the highly effective therapy to the country e...

Study suggests prehabilitation as effective way to improve cancer patient outcomes

"Prehab could be a relatively cheap way to get people ready for cancer treatment and surgery, both of them stressors,” says Dr. Francesco Carli, a professor at McGill University.

Lexicon Pharmaceuticals Reports Positive Top-Line Results For Pivotal Phase 3 Telotristat Etiprate Study In Cancer Patients With Carcinoid Syndrome

THE WOODLANDS, Texas, Aug. 3, 2015 /PRNewswire/ -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced that the pivotal TELESTAR Phase 3 clinical trial met its primary endpoint, showing the benefit of oral telotristat etiprate in treating cancer patients with carcinoid syndrome that is not adequately controlled by the current standard of care. Telotristat etiprate was discovered usin...

5 things about Congress' fight over Planned Parenthood

Republicans will likely lose Monday's Senate showdown over halting federal aid to Planned Parenthood. Yet the political offensive by abortion foes has just started, prompted by a batch of unsettling videos that has focused attention on the group's li...

Hard liquor: Officials seize Chinese spirits laced with Viagra

Chinese authorities have seized thousands of bottles of spirits laced with chemicals used to make erectile dysfunction drugs such as Viagra, officials said.

'Brain training' app may improve memory and daily functioning of people with schizophrenia

A 'brain training' iPad game developed and tested by researchers at the University of Cambridge may improve the memory of patients with schizophrenia, helping them in their daily lives at work and living independently, according to research published...

Novartis completes divestiture of influenza vaccines business to CSL Limited for USD 275 million

Novartis International AG / Novartis completes divestiture of influenza vaccines business to CSL Limited for USD 275 million . Processed and transmitted by NASDAQ OMX Corporate Solutions. The issuer is solely responsible for the content of this announcement. CSL Limited acquired influenza vaccines business of Novartis, including influenza vaccines development pipeline Basel, Switze...

Stalled TPP gives generics more time to push back

USTR chief Michael Froman said the next round of talks has not yet been scheduled, although there were some rumors the negotiators could try again later this month.

Critical thinking

Assessing the Darwinian model of mutation in pharmaceutical companies

Blue Belt Technologies & Acibadem Healthcare Group Announces Formation of World-Class Orthopaedic Surgical Robotics Center and the First Clinical Navio Case Using the Smith & Nephew Journey Uni-Compartmental Knee System

ISTANBUL, TURKEY--(Marketwired - August 03, 2015) - Acibadem Healthcare Group, the leading healthcare services provider in Turkey, and Blue Belt Technologies announces the formation of an Orthopedic Surgical Robotics program as a leading global partner under Blue Belt Technologies' Center of Excellence program. Acibadem Healthcare Group has acquired two Navio® Surgical Systems for establishing bo...



Advertisement
 
Advertisement
 

BioPortfolio's biotechnology, pharmaceutical, healthcare and medical device information service collates press releases, news articles and blogs from over 275 sources.